- Home
- AOD vs IMNM Comparison
AOD vs IMNM Comparison
Compare AOD & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AOD
- IMNM
- Stock Information
- Founded
- AOD 2006
- IMNM 2006
- Country
- AOD United Kingdom
- IMNM United States
- Employees
- AOD N/A
- IMNM N/A
- Industry
- AOD Investment Managers
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- AOD Finance
- IMNM Health Care
- Exchange
- AOD Nasdaq
- IMNM Nasdaq
- Market Cap
- AOD 862.4M
- IMNM 748.3M
- IPO Year
- AOD N/A
- IMNM 2020
- Fundamental
- Price
- AOD $9.02
- IMNM $8.84
- Analyst Decision
- AOD
- IMNM Strong Buy
- Analyst Count
- AOD 0
- IMNM 5
- Target Price
- AOD N/A
- IMNM $26.40
- AVG Volume (30 Days)
- AOD 423.5K
- IMNM 1.0M
- Earning Date
- AOD 01-01-0001
- IMNM 08-11-2025
- Dividend Yield
- AOD 12.95%
- IMNM N/A
- EPS Growth
- AOD 213.63
- IMNM N/A
- EPS
- AOD 1.93
- IMNM N/A
- Revenue
- AOD $72,962,082.00
- IMNM $10,938,000.00
- Revenue This Year
- AOD N/A
- IMNM N/A
- Revenue Next Year
- AOD N/A
- IMNM $310.65
- P/E Ratio
- AOD $4.44
- IMNM N/A
- Revenue Growth
- AOD N/A
- IMNM N/A
- 52 Week Low
- AOD $6.99
- IMNM $5.15
- 52 Week High
- AOD $9.14
- IMNM $16.81
- Technical
- Relative Strength Index (RSI)
- AOD 75.19
- IMNM 50.27
- Support Level
- AOD $8.65
- IMNM $8.35
- Resistance Level
- AOD $8.74
- IMNM $9.34
- Average True Range (ATR)
- AOD 0.07
- IMNM 0.53
- MACD
- AOD 0.03
- IMNM -0.07
- Stochastic Oscillator
- AOD 98.08
- IMNM 33.97
About AOD abrdn Total Dynamic Dividend Fund of Beneficial Interest
Aberdeen Total Dynamic Dividend Fund is a diversified, closed-end management investment company. Its investment objective is to seek high current dividend income. The company also focuses on the long-term growth of capital as a secondary investment objective. The fund invests in foreign securities, including direct investments in securities of foreign issuers and investments in depositary receipts that represent indirect interests in securities of foreign issuers. Its portfolio consists of securities from Information Technology, Financial, Healthcare, and Industrials among other sectors.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.